Pentagestrone

Pentagestrone
Clinical data
Other names17α-Hydroxyprogesterone 3-cyclopentyl enol ether
Drug classProgestogen ether
Identifiers
  • 1-[(8R,9S,10R,13S,14S,17R)-3-cyclopentyloxy-17-hydroxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]ethanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC26H38O3
Molar mass398.587 g·mol−1
3D model (JSmol)
  • CC(=O)C1(CCC2C1(CCC3C2CC=C4C3(CCC(=C4)OC5CCCC5)C)C)O
  • InChI=1S/C26H38O3/c1-17(27)26(28)15-12-23-21-9-8-18-16-20(29-19-6-4-5-7-19)10-13-24(18,2)22(21)11-14-25(23,26)3/h8,16,19,21-23,28H,4-7,9-15H2,1-3H3/t21-,22+,23+,24+,25+,26+/m1/s1
  • Key:RBFQPFFCDLXWQK-UXUCURBISA-N

Pentagestrone (INNTooltip International Nonproprietary Name), also known as 17α-hydroxyprogesterone 3-cyclopentyl enol ether, is a steroidal progestin of the 17α-hydroxyprogesterone group that was never marketed.[1][2] An acetate ester, pentagestrone acetate (Gestovis, Gestovister), has been marketed for clinical use.[1] Pentagestrone was described in the literature in 1960.[1]

  1. ^ a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 943–. ISBN 978-1-4757-2085-3.
  2. ^ Wermuth CG (2 May 2011). The Practice of Medicinal Chemistry. Academic Press. pp. 731–. ISBN 978-0-08-056877-5.